Survival of pancreatic cancer cells lacking KRAS function

Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic ductal adenocarcinoma (PDAC), an aggressive malignancy with few effective therapeutic options. Despite efforts to develop KRAS-targeted drugs, the absolute dependence of PDAC cells on KRAS remains incompletely understood. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Muzumdar, Mandar Deepak, Chen, Pan-Yu, Dorans, Kimberly Judith, Chung, Katherine Minjee, Bhutkar, Arjun, Hong, Erin, Noll, Elisa M., Sprick, Martin R., Trumpp, Andreas, Jacks, Tyler
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653666/
https://www.ncbi.nlm.nih.gov/pubmed/29061961
http://dx.doi.org/10.1038/s41467-017-00942-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653666/
https://www.ncbi.nlm.nih.gov/pubmed/29061961
http://dx.doi.org/10.1038/s41467-017-00942-5

Ejemplares similares